FY2024 Earnings Forecast for Qiagen Issued By Zacks Research

Qiagen (NYSE:QGEN) – Stock analysts at Zacks Research boosted their FY2024 earnings per share estimates for shares of Qiagen in a research note issued to investors on Wednesday, November 27th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $2.17 for the year, up from their prior forecast of $2.14. The consensus estimate for Qiagen’s current full-year earnings is $2.18 per share. Zacks Research also issued estimates for Qiagen’s Q1 2025 earnings at $0.49 EPS, Q3 2025 earnings at $0.57 EPS, Q4 2025 earnings at $0.62 EPS, FY2025 earnings at $2.25 EPS, Q2 2026 earnings at $0.60 EPS, Q3 2026 earnings at $0.65 EPS and FY2026 earnings at $2.45 EPS.

Several other equities analysts have also commented on the company. HSBC lowered Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target on the stock. in a research report on Thursday, October 17th. Hsbc Global Res upgraded shares of Qiagen to a “hold” rating in a research note on Thursday, October 17th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Qiagen currently has a consensus rating of “Moderate Buy” and an average price target of $50.88.

Qiagen Stock Performance

NYSE:QGEN opened at $43.43 on Monday. The firm’s fifty day simple moving average is $43.22 and its 200 day simple moving average is $43.70. The firm has a market capitalization of $9.91 billion, a price-to-earnings ratio of 111.36, a PEG ratio of 3.37 and a beta of 0.41. Qiagen has a twelve month low of $39.03 and a twelve month high of $47.44. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39.

Institutional Trading of Qiagen

Several large investors have recently added to or reduced their stakes in the business. Tidal Investments LLC acquired a new position in shares of Qiagen during the 3rd quarter valued at $490,000. Wilmington Savings Fund Society FSB acquired a new position in Qiagen during the third quarter worth about $53,000. Sanctuary Advisors LLC raised its position in Qiagen by 24.8% in the third quarter. Sanctuary Advisors LLC now owns 19,506 shares of the company’s stock worth $834,000 after acquiring an additional 3,878 shares in the last quarter. M&T Bank Corp lifted its holdings in Qiagen by 1.1% in the 3rd quarter. M&T Bank Corp now owns 85,649 shares of the company’s stock valued at $3,876,000 after acquiring an additional 931 shares during the last quarter. Finally, Barclays PLC boosted its position in shares of Qiagen by 170.6% during the 3rd quarter. Barclays PLC now owns 1,849,004 shares of the company’s stock valued at $84,259,000 after purchasing an additional 1,165,594 shares in the last quarter. 70.00% of the stock is currently owned by institutional investors and hedge funds.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.